Market News AIOpen the app

XERS stock news · Xeris Biopharma Holdings, Inc.

Stories about Xeris Biopharma Holdings, Inc. (XERS) from the last 90 days, each explained in plain English with whether the news reads good or bad for the company.

Get alerts for XERS

Follow Xeris Biopharma Holdings, Inc. (XERS) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for XERS
Free on the App Store and Google Play, or on the web.
  1. Nov 2, 2026, 8:11 AM ET · Market

    Xeris Biopharma is adding Menassie Taddese to its Board of Directors, making the board nine members starting November 2, 2026.

    Neutral

    Xeris added Menassie Taddese to its board and audit committee, with an initial award worth about $450,000 and future annual awards near $300,000. This does not clearly change Xeris's outlook.

  2. Oct 6, 2026, 6:30 AM ET · Results

    Xeris Biopharma Holdings shares what happened during their earnings call for the second quarter of 2026.

    Good for XERS

    Xeris reported 34% growth in product sales, led by Recorlev, paid off debt, and raised the bottom of its 2026 sales forecast. This supports a stronger outlook.

  3. Sep 23, 2026, 10:10 AM ET · Market

    TriSalus Life Sciences, Lakefront Biotherapeutics, Editas Medicine, and other big stocks climbed on Wednesday.

    Neutral

    Xeris Biopharma's shares rose about 3.4% to $9.03, but the article gives no new company-specific detail, so this price move alone does not change the outlook.

  4. Sep 9, 2026, 8:39 AM ET · Market

    Xeris Biopharma will hold a webinar about its XP-8121 program on September 9, 2026.

    Neutral

    Xeris announced an XP-8121 webinar with slides and a press release on Sep 9; the filing provides information only and does not change the company's outlook.